nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—FKBP1A—Cyclosporine—systemic lupus erythematosus	0.467	0.747	CbGbCtD
Pimecrolimus—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.0231	0.0369	CbGbCtD
Pimecrolimus—CYP3A4—Dapsone—systemic lupus erythematosus	0.0202	0.0322	CbGbCtD
Pimecrolimus—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.0175	0.0279	CbGbCtD
Pimecrolimus—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.0175	0.0279	CbGbCtD
Pimecrolimus—CYP3A4—Betamethasone—systemic lupus erythematosus	0.015	0.024	CbGbCtD
Pimecrolimus—CYP3A4—Prednisolone—systemic lupus erythematosus	0.0148	0.0237	CbGbCtD
Pimecrolimus—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.014	0.0224	CbGbCtD
Pimecrolimus—CYP3A4—Prednisone—systemic lupus erythematosus	0.014	0.0223	CbGbCtD
Pimecrolimus—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.0132	0.0212	CbGbCtD
Pimecrolimus—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00872	0.0139	CbGbCtD
Pimecrolimus—MTOR—blood plasma—systemic lupus erythematosus	0.00553	0.0993	CbGeAlD
Pimecrolimus—FKBP1A—blood plasma—systemic lupus erythematosus	0.00497	0.0893	CbGeAlD
Pimecrolimus—CYP3A4—urine—systemic lupus erythematosus	0.00311	0.0559	CbGeAlD
Pimecrolimus—MTOR—connective tissue—systemic lupus erythematosus	0.00294	0.0529	CbGeAlD
Pimecrolimus—MTOR—skin of body—systemic lupus erythematosus	0.00266	0.0477	CbGeAlD
Pimecrolimus—FKBP1A—connective tissue—systemic lupus erythematosus	0.00265	0.0476	CbGeAlD
Pimecrolimus—MTOR—kidney—systemic lupus erythematosus	0.00251	0.045	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—systemic lupus erythematosus	0.00239	0.0429	CbGeAlD
Pimecrolimus—FKBP1A—kidney—systemic lupus erythematosus	0.00225	0.0405	CbGeAlD
Pimecrolimus—FKBP1A—cortex of kidney—systemic lupus erythematosus	0.00219	0.0394	CbGeAlD
Pimecrolimus—MTOR—lymphoid tissue—systemic lupus erythematosus	0.00215	0.0387	CbGeAlD
Pimecrolimus—MTOR—tendon—systemic lupus erythematosus	0.00202	0.0363	CbGeAlD
Pimecrolimus—MTOR—bone marrow—systemic lupus erythematosus	0.00196	0.0352	CbGeAlD
Pimecrolimus—FKBP1A—lymphoid tissue—systemic lupus erythematosus	0.00194	0.0348	CbGeAlD
Pimecrolimus—FKBP1A—tendon—systemic lupus erythematosus	0.00182	0.0327	CbGeAlD
Pimecrolimus—MTOR—lung—systemic lupus erythematosus	0.00178	0.0319	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—systemic lupus erythematosus	0.00176	0.0317	CbGeAlD
Pimecrolimus—MTOR—nervous system—systemic lupus erythematosus	0.00164	0.0295	CbGeAlD
Pimecrolimus—CYP3A4—blood plasma—systemic lupus erythematosus	0.00162	0.0292	CbGeAlD
Pimecrolimus—FKBP1A—lung—systemic lupus erythematosus	0.0016	0.0287	CbGeAlD
Pimecrolimus—MTOR—central nervous system—systemic lupus erythematosus	0.00158	0.0284	CbGeAlD
Pimecrolimus—FKBP1A—nervous system—systemic lupus erythematosus	0.00148	0.0266	CbGeAlD
Pimecrolimus—FKBP1A—central nervous system—systemic lupus erythematosus	0.00142	0.0256	CbGeAlD
Pimecrolimus—CYP3A4—kidney—systemic lupus erythematosus	0.000736	0.0132	CbGeAlD
Pimecrolimus—CYP3A4—nervous system—systemic lupus erythematosus	0.000483	0.00868	CbGeAlD
Pimecrolimus—CYP3A4—central nervous system—systemic lupus erythematosus	0.000465	0.00836	CbGeAlD
Pimecrolimus—Malnutrition—Methylprednisolone—systemic lupus erythematosus	0.000184	0.000937	CcSEcCtD
Pimecrolimus—Erythema—Methylprednisolone—systemic lupus erythematosus	0.000184	0.000937	CcSEcCtD
Pimecrolimus—Angioedema—Prednisolone—systemic lupus erythematosus	0.000183	0.000934	CcSEcCtD
Pimecrolimus—Arthralgia—Mycophenolate mofetil—systemic lupus erythematosus	0.000183	0.000932	CcSEcCtD
Pimecrolimus—Breast disorder—Methotrexate—systemic lupus erythematosus	0.000183	0.000931	CcSEcCtD
Pimecrolimus—Hypersensitivity—Azathioprine—systemic lupus erythematosus	0.000182	0.000926	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic lupus erythematosus	0.000182	0.000926	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cyclosporine—systemic lupus erythematosus	0.00018	0.000916	CcSEcCtD
Pimecrolimus—Oedema—Cyclosporine—systemic lupus erythematosus	0.00018	0.000916	CcSEcCtD
Pimecrolimus—Eye disorder—Dexamethasone—systemic lupus erythematosus	0.00018	0.000915	CcSEcCtD
Pimecrolimus—Eye disorder—Betamethasone—systemic lupus erythematosus	0.00018	0.000915	CcSEcCtD
Pimecrolimus—Angioedema—Hydrocortisone—systemic lupus erythematosus	0.000179	0.000912	CcSEcCtD
Pimecrolimus—Infection—Cyclosporine—systemic lupus erythematosus	0.000179	0.00091	CcSEcCtD
Pimecrolimus—Back pain—Triamcinolone—systemic lupus erythematosus	0.000178	0.000909	CcSEcCtD
Pimecrolimus—Nervous system disorder—Cyclosporine—systemic lupus erythematosus	0.000176	0.000899	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Mycophenolate mofetil—systemic lupus erythematosus	0.000176	0.000894	CcSEcCtD
Pimecrolimus—Oedema—Mycophenolate mofetil—systemic lupus erythematosus	0.000176	0.000894	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—systemic lupus erythematosus	0.000175	0.00089	CcSEcCtD
Pimecrolimus—Skin disorder—Cyclosporine—systemic lupus erythematosus	0.000175	0.00089	CcSEcCtD
Pimecrolimus—Infection—Mycophenolate mofetil—systemic lupus erythematosus	0.000174	0.000888	CcSEcCtD
Pimecrolimus—Nervous system disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000172	0.000877	CcSEcCtD
Pimecrolimus—Hypersensitivity—Leflunomide—systemic lupus erythematosus	0.000172	0.000875	CcSEcCtD
Pimecrolimus—Skin disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000171	0.000868	CcSEcCtD
Pimecrolimus—Diarrhoea—Azathioprine—systemic lupus erythematosus	0.000169	0.00086	CcSEcCtD
Pimecrolimus—Angioedema—Triamcinolone—systemic lupus erythematosus	0.000169	0.000859	CcSEcCtD
Pimecrolimus—Angioedema—Methylprednisolone—systemic lupus erythematosus	0.000168	0.000857	CcSEcCtD
Pimecrolimus—Erythema—Dexamethasone—systemic lupus erythematosus	0.000167	0.000853	CcSEcCtD
Pimecrolimus—Erythema—Betamethasone—systemic lupus erythematosus	0.000167	0.000853	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—systemic lupus erythematosus	0.000166	0.000844	CcSEcCtD
Pimecrolimus—Pruritus—Leflunomide—systemic lupus erythematosus	0.000165	0.00084	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cyclosporine—systemic lupus erythematosus	0.000164	0.000835	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisolone—systemic lupus erythematosus	0.000164	0.000834	CcSEcCtD
Pimecrolimus—Oedema—Prednisolone—systemic lupus erythematosus	0.000164	0.000834	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—systemic lupus erythematosus	0.000163	0.000828	CcSEcCtD
Pimecrolimus—Paraesthesia—Cyclosporine—systemic lupus erythematosus	0.000162	0.000823	CcSEcCtD
Pimecrolimus—Cough—Triamcinolone—systemic lupus erythematosus	0.000161	0.00082	CcSEcCtD
Pimecrolimus—Dyspnoea—Cyclosporine—systemic lupus erythematosus	0.00016	0.000817	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mycophenolate mofetil—systemic lupus erythematosus	0.00016	0.000814	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Hydrocortisone—systemic lupus erythematosus	0.00016	0.000814	CcSEcCtD
Pimecrolimus—Oedema—Hydrocortisone—systemic lupus erythematosus	0.00016	0.000814	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—systemic lupus erythematosus	0.00016	0.000813	CcSEcCtD
Pimecrolimus—Diarrhoea—Leflunomide—systemic lupus erythematosus	0.00016	0.000812	CcSEcCtD
Pimecrolimus—Infection—Hydrocortisone—systemic lupus erythematosus	0.000159	0.000809	CcSEcCtD
Pimecrolimus—Paraesthesia—Mycophenolate mofetil—systemic lupus erythematosus	0.000158	0.000803	CcSEcCtD
Pimecrolimus—Vomiting—Azathioprine—systemic lupus erythematosus	0.000157	0.000799	CcSEcCtD
Pimecrolimus—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	0.000157	0.000799	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—systemic lupus erythematosus	0.000157	0.000799	CcSEcCtD
Pimecrolimus—Arthralgia—Methylprednisolone—systemic lupus erythematosus	0.000157	0.000798	CcSEcCtD
Pimecrolimus—Eye disorder—Prednisone—systemic lupus erythematosus	0.000157	0.000797	CcSEcCtD
Pimecrolimus—Dyspnoea—Mycophenolate mofetil—systemic lupus erythematosus	0.000157	0.000797	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—systemic lupus erythematosus	0.000156	0.000794	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—systemic lupus erythematosus	0.000156	0.000794	CcSEcCtD
Pimecrolimus—Rash—Azathioprine—systemic lupus erythematosus	0.000156	0.000793	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	0.000156	0.000793	CcSEcCtD
Pimecrolimus—Dermatitis—Azathioprine—systemic lupus erythematosus	0.000156	0.000792	CcSEcCtD
Pimecrolimus—Flushing—Prednisone—systemic lupus erythematosus	0.000155	0.000792	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	0.000155	0.000791	CcSEcCtD
Pimecrolimus—Skin disorder—Hydrocortisone—systemic lupus erythematosus	0.000155	0.000791	CcSEcCtD
Pimecrolimus—Headache—Azathioprine—systemic lupus erythematosus	0.000155	0.000788	CcSEcCtD
Pimecrolimus—Pain—Cyclosporine—systemic lupus erythematosus	0.000154	0.000784	CcSEcCtD
Pimecrolimus—Constipation—Cyclosporine—systemic lupus erythematosus	0.000154	0.000784	CcSEcCtD
Pimecrolimus—Angioedema—Dexamethasone—systemic lupus erythematosus	0.000153	0.000779	CcSEcCtD
Pimecrolimus—Angioedema—Betamethasone—systemic lupus erythematosus	0.000153	0.000779	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—systemic lupus erythematosus	0.000152	0.000772	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000152	0.000772	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—systemic lupus erythematosus	0.000151	0.00077	CcSEcCtD
Pimecrolimus—Oedema—Triamcinolone—systemic lupus erythematosus	0.000151	0.000767	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Triamcinolone—systemic lupus erythematosus	0.000151	0.000767	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methylprednisolone—systemic lupus erythematosus	0.00015	0.000765	CcSEcCtD
Pimecrolimus—Pain—Mycophenolate mofetil—systemic lupus erythematosus	0.00015	0.000764	CcSEcCtD
Pimecrolimus—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	0.00015	0.000764	CcSEcCtD
Pimecrolimus—Infection—Triamcinolone—systemic lupus erythematosus	0.00015	0.000762	CcSEcCtD
Pimecrolimus—Infection—Methylprednisolone—systemic lupus erythematosus	0.000149	0.00076	CcSEcCtD
Pimecrolimus—Vomiting—Leflunomide—systemic lupus erythematosus	0.000148	0.000755	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	0.000147	0.00075	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Cyclosporine—systemic lupus erythematosus	0.000147	0.000749	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—systemic lupus erythematosus	0.000147	0.000749	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisolone—systemic lupus erythematosus	0.000147	0.000749	CcSEcCtD
Pimecrolimus—Rash—Leflunomide—systemic lupus erythematosus	0.000147	0.000749	CcSEcCtD
Pimecrolimus—Dermatitis—Leflunomide—systemic lupus erythematosus	0.000147	0.000748	CcSEcCtD
Pimecrolimus—Nausea—Azathioprine—systemic lupus erythematosus	0.000147	0.000747	CcSEcCtD
Pimecrolimus—Headache—Leflunomide—systemic lupus erythematosus	0.000146	0.000744	CcSEcCtD
Pimecrolimus—Skin disorder—Methylprednisolone—systemic lupus erythematosus	0.000146	0.000743	CcSEcCtD
Pimecrolimus—Erythema—Prednisone—systemic lupus erythematosus	0.000146	0.000742	CcSEcCtD
Pimecrolimus—Malnutrition—Prednisone—systemic lupus erythematosus	0.000146	0.000742	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	0.000146	0.000742	CcSEcCtD
Pimecrolimus—Paraesthesia—Hydrocortisone—systemic lupus erythematosus	0.000144	0.000731	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000144	0.000731	CcSEcCtD
Pimecrolimus—Urticaria—Cyclosporine—systemic lupus erythematosus	0.000143	0.000728	CcSEcCtD
Pimecrolimus—Abdominal pain—Cyclosporine—systemic lupus erythematosus	0.000142	0.000724	CcSEcCtD
Pimecrolimus—Body temperature increased—Cyclosporine—systemic lupus erythematosus	0.000142	0.000724	CcSEcCtD
Pimecrolimus—Pain—Prednisolone—systemic lupus erythematosus	0.00014	0.000713	CcSEcCtD
Pimecrolimus—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	0.000139	0.00071	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—systemic lupus erythematosus	0.000139	0.000707	CcSEcCtD
Pimecrolimus—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000139	0.000707	CcSEcCtD
Pimecrolimus—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	0.000139	0.000707	CcSEcCtD
Pimecrolimus—Nausea—Leflunomide—systemic lupus erythematosus	0.000139	0.000705	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	0.000138	0.000703	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	0.000137	0.000699	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	0.000137	0.000697	CcSEcCtD
Pimecrolimus—Pain—Hydrocortisone—systemic lupus erythematosus	0.000137	0.000696	CcSEcCtD
Pimecrolimus—Oedema—Dexamethasone—systemic lupus erythematosus	0.000137	0.000696	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	0.000137	0.000696	CcSEcCtD
Pimecrolimus—Oedema—Betamethasone—systemic lupus erythematosus	0.000137	0.000696	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	0.000137	0.000696	CcSEcCtD
Pimecrolimus—Infection—Dexamethasone—systemic lupus erythematosus	0.000136	0.000691	CcSEcCtD
Pimecrolimus—Infection—Betamethasone—systemic lupus erythematosus	0.000136	0.000691	CcSEcCtD
Pimecrolimus—Paraesthesia—Triamcinolone—systemic lupus erythematosus	0.000135	0.000689	CcSEcCtD
Pimecrolimus—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	0.000135	0.000687	CcSEcCtD
Pimecrolimus—Dyspnoea—Triamcinolone—systemic lupus erythematosus	0.000134	0.000684	CcSEcCtD
Pimecrolimus—Nervous system disorder—Betamethasone—systemic lupus erythematosus	0.000134	0.000682	CcSEcCtD
Pimecrolimus—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	0.000134	0.000682	CcSEcCtD
Pimecrolimus—Angioedema—Prednisone—systemic lupus erythematosus	0.000133	0.000678	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	0.000133	0.000675	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—systemic lupus erythematosus	0.000131	0.000666	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	0.000131	0.000666	CcSEcCtD
Pimecrolimus—Urticaria—Prednisolone—systemic lupus erythematosus	0.00013	0.000662	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	0.000129	0.000659	CcSEcCtD
Pimecrolimus—Pain—Triamcinolone—systemic lupus erythematosus	0.000129	0.000656	CcSEcCtD
Pimecrolimus—Pruritus—Cyclosporine—systemic lupus erythematosus	0.000127	0.000648	CcSEcCtD
Pimecrolimus—Urticaria—Hydrocortisone—systemic lupus erythematosus	0.000127	0.000647	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—systemic lupus erythematosus	0.000126	0.000644	CcSEcCtD
Pimecrolimus—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	0.000126	0.000644	CcSEcCtD
Pimecrolimus—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	0.000126	0.000644	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	0.000126	0.000642	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	0.000125	0.000634	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	0.000125	0.000634	CcSEcCtD
Pimecrolimus—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	0.000124	0.000632	CcSEcCtD
Pimecrolimus—Arthralgia—Prednisone—systemic lupus erythematosus	0.000124	0.000632	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	0.000123	0.000628	CcSEcCtD
Pimecrolimus—Diarrhoea—Cyclosporine—systemic lupus erythematosus	0.000123	0.000627	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	0.000123	0.000626	CcSEcCtD
Pimecrolimus—Paraesthesia—Dexamethasone—systemic lupus erythematosus	0.000123	0.000625	CcSEcCtD
Pimecrolimus—Paraesthesia—Betamethasone—systemic lupus erythematosus	0.000123	0.000625	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—systemic lupus erythematosus	0.000122	0.00062	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—systemic lupus erythematosus	0.000122	0.00062	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisolone—systemic lupus erythematosus	0.000121	0.000614	CcSEcCtD
Pimecrolimus—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	0.00012	0.000612	CcSEcCtD
Pimecrolimus—Urticaria—Triamcinolone—systemic lupus erythematosus	0.00012	0.000609	CcSEcCtD
Pimecrolimus—Urticaria—Methylprednisolone—systemic lupus erythematosus	0.000119	0.000608	CcSEcCtD
Pimecrolimus—Body temperature increased—Triamcinolone—systemic lupus erythematosus	0.000119	0.000606	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—systemic lupus erythematosus	0.000119	0.000606	CcSEcCtD
Pimecrolimus—Oedema—Prednisone—systemic lupus erythematosus	0.000119	0.000606	CcSEcCtD
Pimecrolimus—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	0.000119	0.000605	CcSEcCtD
Pimecrolimus—Infection—Prednisone—systemic lupus erythematosus	0.000118	0.000602	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	0.000118	0.000601	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	0.000118	0.000601	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—systemic lupus erythematosus	0.000118	0.0006	CcSEcCtD
Pimecrolimus—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	0.000118	0.0006	CcSEcCtD
Pimecrolimus—Pain—Dexamethasone—systemic lupus erythematosus	0.000117	0.000595	CcSEcCtD
Pimecrolimus—Pain—Betamethasone—systemic lupus erythematosus	0.000117	0.000595	CcSEcCtD
Pimecrolimus—Nervous system disorder—Prednisone—systemic lupus erythematosus	0.000117	0.000594	CcSEcCtD
Pimecrolimus—Skin disorder—Prednisone—systemic lupus erythematosus	0.000116	0.000589	CcSEcCtD
Pimecrolimus—Vomiting—Cyclosporine—systemic lupus erythematosus	0.000114	0.000583	CcSEcCtD
Pimecrolimus—Rash—Cyclosporine—systemic lupus erythematosus	0.000113	0.000578	CcSEcCtD
Pimecrolimus—Dermatitis—Cyclosporine—systemic lupus erythematosus	0.000113	0.000577	CcSEcCtD
Pimecrolimus—Pruritus—Hydrocortisone—systemic lupus erythematosus	0.000113	0.000576	CcSEcCtD
Pimecrolimus—Headache—Cyclosporine—systemic lupus erythematosus	0.000113	0.000574	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	0.000112	0.000569	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	0.000112	0.000569	CcSEcCtD
Pimecrolimus—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	0.000112	0.000568	CcSEcCtD
Pimecrolimus—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	0.000111	0.000565	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	0.000111	0.000564	CcSEcCtD
Pimecrolimus—Rash—Mycophenolate mofetil—systemic lupus erythematosus	0.000111	0.000564	CcSEcCtD
Pimecrolimus—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	0.000111	0.000563	CcSEcCtD
Pimecrolimus—Headache—Mycophenolate mofetil—systemic lupus erythematosus	0.00011	0.00056	CcSEcCtD
Pimecrolimus—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	0.000109	0.000557	CcSEcCtD
Pimecrolimus—Urticaria—Betamethasone—systemic lupus erythematosus	0.000109	0.000553	CcSEcCtD
Pimecrolimus—Urticaria—Dexamethasone—systemic lupus erythematosus	0.000109	0.000553	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	0.000108	0.000552	CcSEcCtD
Pimecrolimus—Body temperature increased—Betamethasone—systemic lupus erythematosus	0.000108	0.00055	CcSEcCtD
Pimecrolimus—Body temperature increased—Dexamethasone—systemic lupus erythematosus	0.000108	0.00055	CcSEcCtD
Pimecrolimus—Abdominal pain—Betamethasone—systemic lupus erythematosus	0.000108	0.00055	CcSEcCtD
Pimecrolimus—Abdominal pain—Dexamethasone—systemic lupus erythematosus	0.000108	0.00055	CcSEcCtD
Pimecrolimus—Nausea—Cyclosporine—systemic lupus erythematosus	0.000107	0.000544	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisone—systemic lupus erythematosus	0.000107	0.000544	CcSEcCtD
Pimecrolimus—Pruritus—Triamcinolone—systemic lupus erythematosus	0.000107	0.000543	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—systemic lupus erythematosus	0.000106	0.000541	CcSEcCtD
Pimecrolimus—Pruritus—Methylprednisolone—systemic lupus erythematosus	0.000106	0.000541	CcSEcCtD
Pimecrolimus—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	0.000104	0.000531	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—systemic lupus erythematosus	0.000104	0.000528	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—LYN—systemic lupus erythematosus	0.000103	0.000843	CbGpPWpGaD
Pimecrolimus—Rash—Prednisolone—systemic lupus erythematosus	0.000103	0.000526	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisolone—systemic lupus erythematosus	0.000103	0.000525	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	0.000103	0.000525	CcSEcCtD
Pimecrolimus—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	0.000103	0.000523	CcSEcCtD
Pimecrolimus—Headache—Prednisolone—systemic lupus erythematosus	0.000103	0.000522	CcSEcCtD
Pimecrolimus—MTOR—Immune System—C4A—systemic lupus erythematosus	0.000102	0.000833	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—C4B—systemic lupus erythematosus	0.000102	0.000833	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—CDKN1B—systemic lupus erythematosus	0.000102	0.000831	CbGpPWpGaD
Pimecrolimus—Constipation—Prednisone—systemic lupus erythematosus	0.000102	0.000518	CcSEcCtD
Pimecrolimus—Vomiting—Hydrocortisone—systemic lupus erythematosus	0.000102	0.000518	CcSEcCtD
Pimecrolimus—Rash—Hydrocortisone—systemic lupus erythematosus	0.000101	0.000513	CcSEcCtD
Pimecrolimus—Dermatitis—Hydrocortisone—systemic lupus erythematosus	0.000101	0.000513	CcSEcCtD
Pimecrolimus—Headache—Hydrocortisone—systemic lupus erythematosus	0.0001	0.00051	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MMP9—systemic lupus erythematosus	0.0001	0.000817	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—CDKN1A—systemic lupus erythematosus	9.98e-05	0.000814	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	9.95e-05	0.000506	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—BLK—systemic lupus erythematosus	9.89e-05	0.000807	CbGpPWpGaD
Pimecrolimus—Infection—Methotrexate—systemic lupus erythematosus	9.88e-05	0.000503	CcSEcCtD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	9.79e-05	0.000799	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR7—systemic lupus erythematosus	9.79e-05	0.000798	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDCD1—systemic lupus erythematosus	9.79e-05	0.000798	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Methotrexate—systemic lupus erythematosus	9.75e-05	0.000497	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	9.73e-05	0.000495	CcSEcCtD
Pimecrolimus—Nausea—Prednisolone—systemic lupus erythematosus	9.73e-05	0.000495	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—CDKN1B—systemic lupus erythematosus	9.73e-05	0.000793	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—CDKN1B—systemic lupus erythematosus	9.68e-05	0.00079	CbGpPWpGaD
Pimecrolimus—Pruritus—Betamethasone—systemic lupus erythematosus	9.67e-05	0.000492	CcSEcCtD
Pimecrolimus—Pruritus—Dexamethasone—systemic lupus erythematosus	9.67e-05	0.000492	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—systemic lupus erythematosus	9.66e-05	0.000492	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—CDKN1B—systemic lupus erythematosus	9.63e-05	0.000786	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—XRCC6—systemic lupus erythematosus	9.6e-05	0.000783	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—CDKN1B—systemic lupus erythematosus	9.58e-05	0.000782	CbGpPWpGaD
Pimecrolimus—Vomiting—Triamcinolone—systemic lupus erythematosus	9.58e-05	0.000488	CcSEcCtD
Pimecrolimus—Vomiting—Methylprednisolone—systemic lupus erythematosus	9.55e-05	0.000486	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—CDKN1A—systemic lupus erythematosus	9.55e-05	0.000779	CbGpPWpGaD
Pimecrolimus—Nausea—Hydrocortisone—systemic lupus erythematosus	9.5e-05	0.000484	CcSEcCtD
Pimecrolimus—Rash—Triamcinolone—systemic lupus erythematosus	9.5e-05	0.000483	CcSEcCtD
Pimecrolimus—Dermatitis—Triamcinolone—systemic lupus erythematosus	9.49e-05	0.000483	CcSEcCtD
Pimecrolimus—Rash—Methylprednisolone—systemic lupus erythematosus	9.47e-05	0.000482	CcSEcCtD
Pimecrolimus—Dermatitis—Methylprednisolone—systemic lupus erythematosus	9.47e-05	0.000482	CcSEcCtD
Pimecrolimus—Urticaria—Prednisone—systemic lupus erythematosus	9.45e-05	0.000481	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—systemic lupus erythematosus	9.44e-05	0.000771	CbGpPWpGaD
Pimecrolimus—Headache—Triamcinolone—systemic lupus erythematosus	9.43e-05	0.00048	CcSEcCtD
Pimecrolimus—Headache—Methylprednisolone—systemic lupus erythematosus	9.41e-05	0.000479	CcSEcCtD
Pimecrolimus—Body temperature increased—Prednisone—systemic lupus erythematosus	9.41e-05	0.000479	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—systemic lupus erythematosus	9.41e-05	0.000479	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—CDKN1A—systemic lupus erythematosus	9.4e-05	0.000767	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—systemic lupus erythematosus	9.39e-05	0.000766	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Dexamethasone—systemic lupus erythematosus	9.35e-05	0.000476	CcSEcCtD
Pimecrolimus—Diarrhoea—Betamethasone—systemic lupus erythematosus	9.35e-05	0.000476	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—systemic lupus erythematosus	9.33e-05	0.000761	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	9.28e-05	0.000757	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	9.15e-05	0.000747	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CR1—systemic lupus erythematosus	9.1e-05	0.000742	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—systemic lupus erythematosus	9.07e-05	0.00074	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	9.06e-05	0.000461	CcSEcCtD
Pimecrolimus—MTOR—DAP12 interactions—CDKN1B—systemic lupus erythematosus	9.02e-05	0.000736	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1B—systemic lupus erythematosus	9.02e-05	0.000736	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—CDKN1B—systemic lupus erythematosus	9.02e-05	0.000736	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EP300—systemic lupus erythematosus	8.99e-05	0.000733	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—systemic lupus erythematosus	8.99e-05	0.000733	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—CDKN1A—systemic lupus erythematosus	8.98e-05	0.000732	CbGpPWpGaD
Pimecrolimus—Nausea—Triamcinolone—systemic lupus erythematosus	8.95e-05	0.000455	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—CDKN1B—systemic lupus erythematosus	8.93e-05	0.000729	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—CDKN1A—systemic lupus erythematosus	8.93e-05	0.000729	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Methotrexate—systemic lupus erythematosus	8.93e-05	0.000455	CcSEcCtD
Pimecrolimus—Nausea—Methylprednisolone—systemic lupus erythematosus	8.93e-05	0.000454	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—TLR9—systemic lupus erythematosus	8.89e-05	0.000726	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—CDKN1A—systemic lupus erythematosus	8.89e-05	0.000725	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Methotrexate—systemic lupus erythematosus	8.87e-05	0.000451	CcSEcCtD
Pimecrolimus—MTOR—Disease—XRCC6—systemic lupus erythematosus	8.86e-05	0.000723	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—CDKN1B—systemic lupus erythematosus	8.86e-05	0.000723	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—CDKN1A—systemic lupus erythematosus	8.84e-05	0.000722	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTPRC—systemic lupus erythematosus	8.84e-05	0.000721	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—CDKN1B—systemic lupus erythematosus	8.82e-05	0.000719	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Prednisone—systemic lupus erythematosus	8.77e-05	0.000446	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—systemic lupus erythematosus	8.75e-05	0.000714	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—systemic lupus erythematosus	8.75e-05	0.000714	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1A—systemic lupus erythematosus	8.72e-05	0.000711	CbGpPWpGaD
Pimecrolimus—Vomiting—Dexamethasone—systemic lupus erythematosus	8.69e-05	0.000442	CcSEcCtD
Pimecrolimus—Vomiting—Betamethasone—systemic lupus erythematosus	8.69e-05	0.000442	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CFB—systemic lupus erythematosus	8.68e-05	0.000708	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR6—systemic lupus erythematosus	8.68e-05	0.000708	CbGpPWpGaD
Pimecrolimus—Rash—Betamethasone—systemic lupus erythematosus	8.62e-05	0.000439	CcSEcCtD
Pimecrolimus—Rash—Dexamethasone—systemic lupus erythematosus	8.62e-05	0.000439	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—P2RY12—systemic lupus erythematosus	8.61e-05	0.000703	CbGpPWpGaD
Pimecrolimus—Dermatitis—Dexamethasone—systemic lupus erythematosus	8.61e-05	0.000438	CcSEcCtD
Pimecrolimus—Dermatitis—Betamethasone—systemic lupus erythematosus	8.61e-05	0.000438	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	8.59e-05	0.000437	CcSEcCtD
Pimecrolimus—Headache—Dexamethasone—systemic lupus erythematosus	8.56e-05	0.000436	CcSEcCtD
Pimecrolimus—Headache—Betamethasone—systemic lupus erythematosus	8.56e-05	0.000436	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—CD80—systemic lupus erythematosus	8.56e-05	0.000698	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—systemic lupus erythematosus	8.51e-05	0.000695	CbGpPWpGaD
Pimecrolimus—Pain—Methotrexate—systemic lupus erythematosus	8.51e-05	0.000433	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—HMGB1—systemic lupus erythematosus	8.44e-05	0.000688	CbGpPWpGaD
Pimecrolimus—Pruritus—Prednisone—systemic lupus erythematosus	8.42e-05	0.000429	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—CDKN1B—systemic lupus erythematosus	8.34e-05	0.000681	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—CDKN1A—systemic lupus erythematosus	8.32e-05	0.000679	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—CDKN1A—systemic lupus erythematosus	8.32e-05	0.000679	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1A—systemic lupus erythematosus	8.32e-05	0.000679	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IFNA1—systemic lupus erythematosus	8.29e-05	0.000676	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—CDKN1A—systemic lupus erythematosus	8.25e-05	0.000673	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40—systemic lupus erythematosus	8.22e-05	0.000671	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—systemic lupus erythematosus	8.17e-05	0.000667	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Prednisone—systemic lupus erythematosus	8.14e-05	0.000415	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—CDKN1A—systemic lupus erythematosus	8.14e-05	0.000664	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	8.13e-05	0.000664	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	8.13e-05	0.000414	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—JUNB—systemic lupus erythematosus	8.12e-05	0.000663	CbGpPWpGaD
Pimecrolimus—Nausea—Betamethasone—systemic lupus erythematosus	8.12e-05	0.000413	CcSEcCtD
Pimecrolimus—Nausea—Dexamethasone—systemic lupus erythematosus	8.12e-05	0.000413	CcSEcCtD
Pimecrolimus—MTOR—Immune System—FCGR3A—systemic lupus erythematosus	8.11e-05	0.000662	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CTLA4—systemic lupus erythematosus	8.1e-05	0.000661	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RASGRP1—systemic lupus erythematosus	8.07e-05	0.000659	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RIPK1—systemic lupus erythematosus	8.01e-05	0.000654	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1B—systemic lupus erythematosus	7.98e-05	0.000651	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CSK—systemic lupus erythematosus	7.93e-05	0.000647	CbGpPWpGaD
Pimecrolimus—Urticaria—Methotrexate—systemic lupus erythematosus	7.9e-05	0.000402	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—systemic lupus erythematosus	7.87e-05	0.000642	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Methotrexate—systemic lupus erythematosus	7.86e-05	0.0004	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—systemic lupus erythematosus	7.86e-05	0.0004	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—systemic lupus erythematosus	7.76e-05	0.000633	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RASGRP1—systemic lupus erythematosus	7.75e-05	0.000632	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR9—systemic lupus erythematosus	7.74e-05	0.000631	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD79A—systemic lupus erythematosus	7.73e-05	0.00063	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CDKN1A—systemic lupus erythematosus	7.7e-05	0.000628	CbGpPWpGaD
Pimecrolimus—Vomiting—Prednisone—systemic lupus erythematosus	7.57e-05	0.000385	CcSEcCtD
Pimecrolimus—Rash—Prednisone—systemic lupus erythematosus	7.5e-05	0.000382	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—systemic lupus erythematosus	7.5e-05	0.000382	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—PRL—systemic lupus erythematosus	7.49e-05	0.000611	CbGpPWpGaD
Pimecrolimus—Headache—Prednisone—systemic lupus erythematosus	7.46e-05	0.00038	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—systemic lupus erythematosus	7.37e-05	0.000601	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Methotrexate—systemic lupus erythematosus	7.33e-05	0.000373	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—systemic lupus erythematosus	7.32e-05	0.000597	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—systemic lupus erythematosus	7.27e-05	0.000593	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NCF2—systemic lupus erythematosus	7.25e-05	0.000592	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—TYK2—systemic lupus erythematosus	7.22e-05	0.000589	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LYN—systemic lupus erythematosus	7.2e-05	0.000588	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DQA1—systemic lupus erythematosus	7.13e-05	0.000582	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisone—systemic lupus erythematosus	7.07e-05	0.00036	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—SH2B3—systemic lupus erythematosus	7.07e-05	0.000576	CbGpPWpGaD
Pimecrolimus—Pruritus—Methotrexate—systemic lupus erythematosus	7.04e-05	0.000358	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CSK—systemic lupus erythematosus	6.9e-05	0.000563	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MBL2—systemic lupus erythematosus	6.84e-05	0.000558	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Methotrexate—systemic lupus erythematosus	6.8e-05	0.000346	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IRF5—systemic lupus erythematosus	6.78e-05	0.000553	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DQB1—systemic lupus erythematosus	6.67e-05	0.000544	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN1B—systemic lupus erythematosus	6.55e-05	0.000534	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIST2H2AC—systemic lupus erythematosus	6.53e-05	0.000533	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFIH1—systemic lupus erythematosus	6.48e-05	0.000529	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRF8—systemic lupus erythematosus	6.48e-05	0.000529	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ITGAM—systemic lupus erythematosus	6.48e-05	0.000529	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD247—systemic lupus erythematosus	6.48e-05	0.000529	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CSK—systemic lupus erythematosus	6.37e-05	0.000519	CbGpPWpGaD
Pimecrolimus—Vomiting—Methotrexate—systemic lupus erythematosus	6.32e-05	0.000322	CcSEcCtD
Pimecrolimus—MTOR—Immune System—NCF2—systemic lupus erythematosus	6.31e-05	0.000515	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40LG—systemic lupus erythematosus	6.3e-05	0.000514	CbGpPWpGaD
Pimecrolimus—Rash—Methotrexate—systemic lupus erythematosus	6.27e-05	0.000319	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—systemic lupus erythematosus	6.27e-05	0.000319	CcSEcCtD
Pimecrolimus—MTOR—Immune System—LYN—systemic lupus erythematosus	6.27e-05	0.000511	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—JAK1—systemic lupus erythematosus	6.26e-05	0.000511	CbGpPWpGaD
Pimecrolimus—Headache—Methotrexate—systemic lupus erythematosus	6.23e-05	0.000317	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—systemic lupus erythematosus	6.23e-05	0.000508	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—systemic lupus erythematosus	6.22e-05	0.000508	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FCGR2A—systemic lupus erythematosus	6.18e-05	0.000505	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CDKN1B—systemic lupus erythematosus	6.14e-05	0.000501	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TNFAIP3—systemic lupus erythematosus	6.07e-05	0.000495	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN1A—systemic lupus erythematosus	6.04e-05	0.000493	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BLK—systemic lupus erythematosus	6e-05	0.000489	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—JAK1—systemic lupus erythematosus	5.99e-05	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD247—systemic lupus erythematosus	5.99e-05	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—systemic lupus erythematosus	5.95e-05	0.000486	CbGpPWpGaD
Pimecrolimus—Nausea—Methotrexate—systemic lupus erythematosus	5.91e-05	0.000301	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—systemic lupus erythematosus	5.86e-05	0.000478	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NCF2—systemic lupus erythematosus	5.82e-05	0.000475	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—C3—systemic lupus erythematosus	5.8e-05	0.000473	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL12—systemic lupus erythematosus	5.8e-05	0.000473	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—EP300—systemic lupus erythematosus	5.75e-05	0.000469	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JUNB—systemic lupus erythematosus	5.69e-05	0.000464	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CCR5—systemic lupus erythematosus	5.67e-05	0.000463	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CDKN1A—systemic lupus erythematosus	5.67e-05	0.000462	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—systemic lupus erythematosus	5.59e-05	0.000456	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—C3—systemic lupus erythematosus	5.57e-05	0.000454	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—systemic lupus erythematosus	5.57e-05	0.000454	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—systemic lupus erythematosus	5.54e-05	0.000452	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CRP—systemic lupus erythematosus	5.52e-05	0.00045	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—systemic lupus erythematosus	5.51e-05	0.00045	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—systemic lupus erythematosus	5.45e-05	0.000444	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RASGRP1—systemic lupus erythematosus	5.41e-05	0.000441	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPRC—systemic lupus erythematosus	5.36e-05	0.000438	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1RN—systemic lupus erythematosus	5.34e-05	0.000436	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—systemic lupus erythematosus	5.29e-05	0.000431	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PRL—systemic lupus erythematosus	5.24e-05	0.000428	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	5.2e-05	0.000424	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—systemic lupus erythematosus	5.19e-05	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—systemic lupus erythematosus	5.19e-05	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—systemic lupus erythematosus	5.19e-05	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—systemic lupus erythematosus	5.14e-05	0.000419	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—systemic lupus erythematosus	5.09e-05	0.000416	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DRB1—systemic lupus erythematosus	5.07e-05	0.000414	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—systemic lupus erythematosus	5.07e-05	0.000414	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TLR9—systemic lupus erythematosus	5e-05	0.000408	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40—systemic lupus erythematosus	4.99e-05	0.000407	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTLA4—systemic lupus erythematosus	4.91e-05	0.000401	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HMGB1—systemic lupus erythematosus	4.91e-05	0.000401	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD80—systemic lupus erythematosus	4.88e-05	0.000398	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—P2RY12—systemic lupus erythematosus	4.84e-05	0.000395	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA1—systemic lupus erythematosus	4.83e-05	0.000394	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RASGRP1—systemic lupus erythematosus	4.7e-05	0.000384	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD79A—systemic lupus erythematosus	4.69e-05	0.000382	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD80—systemic lupus erythematosus	4.69e-05	0.000382	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD80—systemic lupus erythematosus	4.67e-05	0.000381	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—systemic lupus erythematosus	4.59e-05	0.000375	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	4.57e-05	0.000373	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JUNB—systemic lupus erythematosus	4.57e-05	0.000373	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PRL—systemic lupus erythematosus	4.56e-05	0.000372	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CSK—systemic lupus erythematosus	4.46e-05	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DQA1—systemic lupus erythematosus	4.33e-05	0.000353	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PRL—systemic lupus erythematosus	4.21e-05	0.000343	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JAK1—systemic lupus erythematosus	4.19e-05	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TYK2—systemic lupus erythematosus	4.12e-05	0.000336	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCF2—systemic lupus erythematosus	4.08e-05	0.000333	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LYN—systemic lupus erythematosus	4.05e-05	0.00033	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DQB1—systemic lupus erythematosus	4.05e-05	0.00033	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SH2B3—systemic lupus erythematosus	3.97e-05	0.000324	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR5—systemic lupus erythematosus	3.97e-05	0.000324	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TYK2—systemic lupus erythematosus	3.94e-05	0.000321	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2RA—systemic lupus erythematosus	3.92e-05	0.000319	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—C3—systemic lupus erythematosus	3.88e-05	0.000317	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS3—systemic lupus erythematosus	3.87e-05	0.000315	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL18—systemic lupus erythematosus	3.84e-05	0.000313	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—systemic lupus erythematosus	3.82e-05	0.000312	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—systemic lupus erythematosus	3.78e-05	0.000308	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—systemic lupus erythematosus	3.77e-05	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—systemic lupus erythematosus	3.73e-05	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JAK1—systemic lupus erythematosus	3.65e-05	0.000298	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—systemic lupus erythematosus	3.58e-05	0.000292	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—systemic lupus erythematosus	3.56e-05	0.000291	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—systemic lupus erythematosus	3.54e-05	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—systemic lupus erythematosus	3.53e-05	0.000288	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1B—systemic lupus erythematosus	3.5e-05	0.000286	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—F2—systemic lupus erythematosus	3.41e-05	0.000278	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2RA—systemic lupus erythematosus	3.41e-05	0.000278	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—C3—systemic lupus erythematosus	3.38e-05	0.000276	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JAK1—systemic lupus erythematosus	3.37e-05	0.000275	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1B—systemic lupus erythematosus	3.36e-05	0.000274	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1B—systemic lupus erythematosus	3.35e-05	0.000273	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CD80—systemic lupus erythematosus	3.27e-05	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL12—systemic lupus erythematosus	3.26e-05	0.000266	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1A—systemic lupus erythematosus	3.23e-05	0.000264	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—systemic lupus erythematosus	3.21e-05	0.000262	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUNB—systemic lupus erythematosus	3.2e-05	0.000261	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCR5—systemic lupus erythematosus	3.19e-05	0.00026	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1A—systemic lupus erythematosus	3.1e-05	0.000253	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1A—systemic lupus erythematosus	3.09e-05	0.000252	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—systemic lupus erythematosus	3.08e-05	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRB1—systemic lupus erythematosus	3.08e-05	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EP300—systemic lupus erythematosus	3.08e-05	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RASGRP1—systemic lupus erythematosus	3.04e-05	0.000248	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—systemic lupus erythematosus	3.04e-05	0.000248	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRL—systemic lupus erythematosus	2.95e-05	0.000241	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EP300—systemic lupus erythematosus	2.94e-05	0.00024	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD80—systemic lupus erythematosus	2.84e-05	0.000232	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TYK2—systemic lupus erythematosus	2.76e-05	0.000225	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—systemic lupus erythematosus	2.71e-05	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD80—systemic lupus erythematosus	2.62e-05	0.000214	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—systemic lupus erythematosus	2.56e-05	0.000209	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TYK2—systemic lupus erythematosus	2.4e-05	0.000196	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAK1—systemic lupus erythematosus	2.36e-05	0.000192	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.35e-05	0.000191	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—systemic lupus erythematosus	2.3e-05	0.000187	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—systemic lupus erythematosus	2.25e-05	0.000183	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR5—systemic lupus erythematosus	2.23e-05	0.000182	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TYK2—systemic lupus erythematosus	2.22e-05	0.000181	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2RA—systemic lupus erythematosus	2.2e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—C3—systemic lupus erythematosus	2.18e-05	0.000178	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—systemic lupus erythematosus	2.17e-05	0.000177	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—systemic lupus erythematosus	2.17e-05	0.000177	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—systemic lupus erythematosus	2.17e-05	0.000177	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.16e-05	0.000177	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—systemic lupus erythematosus	2.06e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—systemic lupus erythematosus	2.04e-05	0.000166	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—systemic lupus erythematosus	2.01e-05	0.000164	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—systemic lupus erythematosus	2e-05	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—systemic lupus erythematosus	2e-05	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—systemic lupus erythematosus	1.99e-05	0.000162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.95e-05	0.000159	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—systemic lupus erythematosus	1.93e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—F2—systemic lupus erythematosus	1.92e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—systemic lupus erythematosus	1.88e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—systemic lupus erythematosus	1.88e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD80—systemic lupus erythematosus	1.84e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—systemic lupus erythematosus	1.79e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.79e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—systemic lupus erythematosus	1.74e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—systemic lupus erythematosus	1.71e-05	0.000139	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—systemic lupus erythematosus	1.65e-05	0.000135	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	1.59e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TYK2—systemic lupus erythematosus	1.55e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—systemic lupus erythematosus	1.52e-05	0.000124	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—systemic lupus erythematosus	1.44e-05	0.000117	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—systemic lupus erythematosus	1.35e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.32e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—systemic lupus erythematosus	1.29e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—systemic lupus erythematosus	1.22e-05	9.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.22e-05	9.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—systemic lupus erythematosus	1.17e-05	9.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—systemic lupus erythematosus	1.16e-05	9.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.1e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—systemic lupus erythematosus	1.08e-05	8.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.01e-05	8.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	8.89e-06	7.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—systemic lupus erythematosus	7.59e-06	6.19e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	5.62e-06	4.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	5.05e-06	4.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	4.83e-06	3.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	4.42e-06	3.6e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	3.67e-06	3e-05	CbGpPWpGaD
